Market Notice 82/19 – Information regarding PharmaLundensis AB’s convertible loan

According to a decision by PharmaLundensis AB’s (the Company) board, the Company will issue a convertible loan. The record date is April 11, 2019.

One (1) share (PHAL) entitles the owner to one (1) subscription right. Seventy-one (71) subscription rights entitles the owner to subscribe for one (1) convertible loan at a subscription price of SEK 15,00. The subscription period last from April 15, 2019 to April 30, 2019.

For further information please see todays press release from the company.

Note, the subscription right, the paid subscribed unit and the convertible loan will not be traded at Spotlight Stock Market.

Information about the share:  
Short name: PHAL 
ISIN-code: SE0003359710 
Orderbook-ID: 4110 
CFI: ESVUFR 
FISN: PHARMALUND/SH 
Market segment: SPSE 
MIC Code: XSAT  

Stockholm April 4, 2019

Spotlight Stock Market
08-511 68 000
info@spotlightstockmarket.com 

Om oss

PharmaLundensis affärsidé är att utveckla nya och kreativa läkemedel mot sjukdomar som idag saknar effektiv behandling. En ny behandling mot den svåra lungsjukdomen KOL med IodoCarb® befinner sig i klinisk fas, och bolaget avser inom kort att starta kliniska studier mot fler svårbehandlade sjukdomar.

Prenumerera

Dokument & länkar